PTIXW Protagenic Therapeutics, Inc. Warrant

Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.  This security was issued by Protagenic Therapeutics Inc., whose common stock symbol is PTIX.

$0.04  0.00 (0.00%)
As of 03/24/2023 00:00:00 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Warrants
Category3:  Operating Companies
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  04/27/2021
Outstanding shares:  3,180,000
Average volume:  4,420
Market cap:   $29,944,725
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol: